<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233074</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0701</org_study_id>
    <secondary_id>2017-A02088-45</secondary_id>
    <nct_id>NCT03233074</nct_id>
  </id_info>
  <brief_title>Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors</brief_title>
  <acronym>COSMOS</acronym>
  <official_title>Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (COSMOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is of clinical significance to better characterize the intrinsic defects harbored by
      mesenchymal stromal cells (MSC) in Myelodysplastic syndromes (MDS) and acute myeloid leukemia
      (AML) context, as compared to physiological conditions. Such research initiative aims to
      dissect the cross-talk between malignant hematopoietic stem cells (HSC) and their bone marrow
      (BM) partners in crime, further prospecting for innovative stromal-directed strategies for
      the treatment of Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal malignancies that are
      characterized by ineffective hematopoiesis, progressive bone marrow failure, cytogenetic and
      molecular abnormalities, and increased risk for progression to acute myeloid leukemia (AML).
      It is a well-accepted theory that MDS and AML originate from primary alterations of
      hematopoietic stem cells (HSC) compartment, which confer a survival advantage to them at the
      expense of physiological hematopoiesis. More recently, there is growing evidences regarding
      the contribution of the bone marrow (BM) microenvironment to the pathogenesis of MDS and AML.
      Of particular interest, several studies have pointed towards a pivotal role of mesenchymal
      stromal cells (MSC), one of the main components of the BM niche, in the initiation and
      propagation of myeloid disorders. In this context, it is of clinical significance to better
      characterize the intrinsic defects harbored by MSC in MDS and AML context, as compared to
      physiological conditions. Such research initiative aims to dissect the cross-talk between
      malignant HSC and their BM partners in crime, further prospecting for innovative
      stromal-directed strategies for the treatment of MDS and AML.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cellular properties of mesenchymal stromal cells</measure>
    <time_frame>Day 0</time_frame>
    <description>Changes in cellular properties of mesenchymal stromal cells isolated from bone marrow aspirates by comparing normal cells (i.e. healthy donors) and MDS/AML cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of differential biomarkers in mesenchymal stromal cells</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of differential biomarkers expressed by MDS or AML-derived mesenchymal stromal cells</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Cardio-vascular Surgery</condition>
  <arm_group>
    <arm_group_label>Acute Myeloid Leukemia patients</arm_group_label>
    <description>For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy donors</arm_group_label>
    <description>Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone marrow analyses</intervention_name>
    <description>This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.</description>
    <arm_group_label>Acute Myeloid Leukemia patients</arm_group_label>
    <arm_group_label>Healthy donors</arm_group_label>
    <other_name>Cellular properties of mesenchymal stromal cells</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute Myeloid Leukemia patients undergoing a bone marrow sampling for diagnosis purposes,
        and healthy donors undergoing cardio-vascular surgery for their usual support.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosed myelodysplasia or acute myeloid leukemia (study place: ICLN) -
             Specific to the cases cohort

          -  Age-matched healthy donors undergoing a cardiovascular surgery - Specific to the
             control cohort

          -  Signed written informed consent form

          -  Patient affiliated to a social security regimen or beneficiary of the same

        Exclusion Criteria:

          -  Medical history of hematological disorders

          -  Thrombocytopenia, anemia…

          -  Patient under guardianship or deprived of his liberty or any condition that may affect
             the patient's ability to understand and sign the informed consent (art. L.1121-6,
             L.112-7, L.1211-8, L.1211-9)

          -  Pregnant or breastfeeding women

          -  Refusing participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Guyotat, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Guyotat, PhD</last_name>
    <phone>(0)4 77 91 70 70</phone>
    <phone_ext>+33</phone_ext>
    <email>denis.guyotat@icloire.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Daguenet, PhD</last_name>
    <phone>(0)4 77 91 70 89</phone>
    <phone_ext>+33</phone_ext>
    <email>Elisabeth.daguenet@icloire.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François Fuzelier, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François Fuzelier, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Guyotat, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Denis Guyotat, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme Cornillon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fressia Honeyman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Lejeune, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiane Mounier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle Portois, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilbert Soglu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Tavernier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Bone Marrow</keyword>
  <keyword>Mesenchymal stromal cell</keyword>
  <keyword>Healthy donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

